The function of poliamine metabolism in prostate cancer

Experimental Oncology

Volumn 28, Issue 3, 2006, Pages 178-186

  Palavan Unsal, N ^a   Aloglu Senturk, S M ^a   Arisan, D ^a  

^a HALIC UNIVERSITY   (Turkey)

Author keywords

Bohemine; CDK inhibitors; Olomoucine; Polyamines; Prostate cancer; Roscovitine

Indexed keywords

AZIRIDINYLPUTRESCINE; BIOLOGICAL MARKER; BOHEMINE; BUTYROLACTONE; CAMPTOTHECIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DEXAMETHASONE; EFLORNITHINE; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; INDIRUBIN; METHYLACETYLENIC PUTRESCINE; OLOMOUCINE; ORNITHINE DECARBOXYLASE; ORNITHINE DECARBOXYLASE INHIBITOR; OXALIPLATIN; PAULLONE DERIVATIVE; POLYAMINE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PURVALANOL; ROSCOVITINE; SPERMIDINE; SPERMINE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; HUMAN; IN VITRO STUDY; NONHUMAN; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW;

APOPTOSIS; CELL DIFFERENTIATION; HUMANS; MALE; POLYAMINES; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750952079     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981; 19: 1-20.
2. Tabor CW, Tabor H. Polyamines. Ann Rev Biochem 1984; 53: 749-90.
3. Féray A, Hourmant A, Penot M, Caroff J, Cann-Moisan C. Polyamines and morphogenesis. Effects of methylglyoxal-bis (guanylhydrazone). Bot Acta 1994; 107: 18-21.
4. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243: 212-21.
5. Sjoerdsma A, Schechter PJ. Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther 1984; 35: 287-300.
6. Jänne J, Morris DR. Inhibition of S-adenosylmethionine decarboxylase and diamine oxidase activities by analogues of methylglyoxal bis(guanylhydrazone) and their cellular uptake during lymfocyte activation. Biochem J 1984; 218: 947-51.
7. Seiler N, Bolkenius FN, Knödgen B. The influence of catabolic reactions on polyamine oxidase. Biochem J 1985; 225: 219-26.
8. Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986; 234: 249-62.
9. Hölttä E. Oxidation of spermidine and spermine in rat liver: purification and properties of polyamine oxidase. Biochemistry 1977; 16: 91-100.
10. Pegg AE, Matsui I, Seely JE, Pritchard ML, Peso H. Formation of putrescine in rat liver. Med Biol 1981; 59: 327-33.
11. Matsui I, Wiegand L, Pegg AE. Properties of spermidine N-acetyltransferase from livers of rats treated with carbon tetrachloride and its role in the conversion of spermidine into putrescine. J Biol Chem 1981; 256: 2454-9.
12. Morgan DML. Polyamine oxidases and oxidized polyamines. In: The Physiology of Polyamines. U. Bachrach & Y.M. Heimer, eds. CRC Press: Boca Raton, 1989.
13. Binda C, Mattevi A, Edmondson DE. Structure function relationships in flavoenzyme-dependent amine oxidations: a comparison of polyamine oxidase and monoamine oxidase. J Biol Chem 2002; 277: 23973-6.
14. Keskinege A, Elgun S, Yilmaz E. Possible implications of arginase and diamine oxidase in prostate carcinoma. Cancer Detect Prev 2001; 25: 76-9.
15. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992; 360: 355-8.
16. Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Andersson LC, Holtta E. Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res 1997; 57: 3016-25.
17. O'Brien TG, Megosh LC, Gilliard G, Soler AP. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res 1997; 57: 2630-7.
18. Shantz LM, Pegg AE. Ornithine decarboxylase induction in transformation by H-Ras and RhoA. Cancer Res 1998; 58: 2748-53.
19. Tabib A, Bachrach U. Polyamines induce malignant transformation in cultured NIH 3T3 fibroblasts. Int J Biochem Cell Biol 1998; 30: 135-46.
20. Heby O, Persson L. Molecular genetics of polyamine synthesis in eukaryotic cells. Trends Biochem Sci 1990; 15: 153-8.
21. Hayashi S, Murakami Y, Matsufuji S. Ornithine decarboxylase antizyme: a novel type of regulatory protein. Trends Biochem Sci 1996; 21: 27-30.
22. Murakami Y, Ichiba T, Matshufuji S, Hayashi S. Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase. J Biol Chem 1996; 271: 3340-2.
23. Baeza I, Ibanez M, Wong C, Chavez P, Gariglio P, Oro J. Possible prebiotic significance of polyamines in the condensation, protection, encapsulation, and biological properties of DNA. Orig Life Evol Biosph 1991; 21: 225-42.
24. Matthews HR. Polyamines, chromatin structure and transcription. Bioessays 1993; 15: 561-6.
25. Raspaud E, Chaperon I, Feforestier A, Livolant F. Spermine-induced aggregation of DNA, nucleosome, and chromatin. Biophys J 1999; 77: 1547-55.
26. Bolton PH, Kearns DR. Effect of magnesium and polyamines on the structure of yeast tRNAPhe. Biochim Biophys Acta 1977; 477: 10-9.
27. Heerschap A, Walters JA, Hilbers CW. Interactions of some naturally occurring cations with phenylalanine and initiator tRNA from yeast as reflected by their thermal stability. Biophys Chem 1985; 22: 205-17.
28. Knapp G. Enzymatic approaches to probing of RNA secondary and tertiary structure. Meth Enzymol 1989; 180: 110-7.
29. Park MH, Lee YB, Joe YA. Hypusine is essential for eukaryotic cell proliferation. Biol Signals 1997; 6: 115-23.
30. Williams K. Modulation and block of ion channels: a new biology of polyamines. Cell Signal 1997; 9: 1-13.
31. Heby O, Andersson G, Gray JW. Interference with S and G2 phase progression by polyamine synthesis inhibitors. Exp Cell Res 1978; 111: 461-4.
32. Liu X, Wang L, Lin Y, Teng Q, Zhao C, Hu H, Chui W. Ornithine decarboxylase activity and its gene expression are increased in benign hyperplastic prostate. Prostate 2000; 43: 83-7.
33. Jänne J, Pöso H, Raina A. Polyamines in rapid growth and cancer. Biochim Biophys Acta 1978; 473: 241-93.
34. Fadeel B, Zhivotovsky B, Orrenius S. All along the watchtower: on the regulation of apoptosis regulators. FASEB J 1999; 13: 1647-57.
35. Schipper RG, Penning LC, Verhofstad AAJ. Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? Semin Cancer Biol 2000; 10: 55-68.
36. Bernstein HG, Müller M. The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog Neurobiol 1999; 57: 485-505.
37. Packham G, Cleveland JL. Ornithine decarboxylase is a mediator of c-myc-induced apoptosis. Mol Cell Biol 1994; 14: 5741-7.
38. Packham G, Porter CW, Cleveland JL. C-myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene 1996; 13: 461-9.
39. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Ann Rev Physiol 1998; 60: 601-17.
40. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003; 376: 1-14.
41. Monti MG, Ghiaroni S, Barbieri D, Franceschi C, Marverti G, Morruzzi MS. 2-Deoxy-D-ribose-induced apoptosis in HL-60 cells is associated with the cell cycle progression by spermidine. Biochem Biophys Res Commun 1999; 257: 460-5.
42. Stefanelli C, Stanic I, Zini M, Bonavita F, Flamigni F, Zambonin L, Landi L, Pignatti C, Guarnieri C, Caldarera CM. Polyamines directly induce release of cytochrome c from heart mitochondria. Biochem J 2000; 347: 875-80.
43. Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett 2000; 466: 6-10.
44. Yuan Q, Ray RM, Johnson LR. Polyamine depletion prevents camptothecin-induced apoptosis by inhibiting the release of cytochrome c. Am J Physiol Cell Physiol 2002; 282: 1290-7.
45. Erez O, Goldstaub d, Friedman J, Kahana C. Putrescine activates oxidative stress dependent apoptotic death in ornithine decarboxylase overproducing mouse myeloma cells. Exp Cell Res 2002; 281: 148-56.
46. Nitta T, Igarashi K, Yamamoto N. Polyamine depletion induces apoptosis through mitochondria-mediated pathway. Exp Cell Res 2002; 276: 120-8.
47. Hegardt C, Andersson G, Oredsson SM. Spermine prevents cytochrome c release in glucocorticoid-induced apoptosis in mouse thymocytes. Cell Biol Int 2003; 27: 115-21.
48. Cipolla BG, Ziade J, Bansard JY, Moulinoux JP, Staerman F, Quemener V, Lobel B, Guille F. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma. Cancer 1996; 78: 1055-65.
49. Matsui-Yuasa I, Otani S, Yano Y, Takada N, Shibata MA, Fukushima S. Spermidine/spermine N1-acetyltransferase, a new biochemical marker for epithelial proliferation in rat bladder. Jpn J Cancer Res 1992; 83: 1037-40.
50. Nishioka K, Melgarejo AB, Lyon RR, Mitchell MF. Polyamines as biomarkers of cervical intraepithelial neoplasia. J Cell Biochem Suppl 1995; 23: 87-95.
51. Porter CW, Regenass U, Bergeron RJ. Polyamine inhibitors and analogues as potential anticancer agents. In: Polyamines in the gastrointestinal tract. Dowling RH, Folsch UR, Loser C, eds. Dordrecht: Kluwer, 1992; 301-19.
52. Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Aim Rev Pharmacol Toxicol 1995; 35: 55-91.
53. Kramer DL. Polyamine inhibitors and analogues. In: Polyamines in Cancer Basic Mechanisms and Clinical Approaches. Nishioka K, ed. Austin, RG Landis, 1996; 151-89.
54. Casero RAJr, Ervin SJ, Celano P, Baylin SB, Bergeron RJ. Differential response to treatment with the bis(ethyl)polyamine analogues between human small cell lung carcinoma and undifferentiated large cell lung carcinoma in culture. Cancer Res 1989; 49: 639-43.
55. Basu HS, Marton LJ, Pellarin M, Deen DF, McManis JS, Liu CZ, Bergeron RJ, Feurstein DG. Design and testing of novel cytotoxic polyamine analogues. Cancer Res 1994; 54: 6210-4.
56. Seiler N. Functions of polyamine acetylation. Can J Physiol Pharmacol 1987; 65: 2024-35.
57. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ, Johnston PG. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003; 63: 4602-6.
58. Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, Powell CT, Kramer DL, Porter CW. Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. J Biol Chem 2004; 26: 27050-8.
59. Greenberg NM, DeMayo MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RS, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-43.
60. Hessels D, Rittenhouse HG, Schalken JA. Molecular diagnostics in prostate cancer. EUA Update Series 2005; 3: 200-13.
61. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50: 3748-53.
62. Lepor H, Ross A, Walsh PC. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982; 128: 335-40.
63. Fjosne HE, Ostensen MA, Haarstad H, Sunder A. Androgen regulation of polyamine synthesis in seminal vesicle and in different lobes of the rat prostate. Prostate 1990; 17: 1-11.
64. Janne J, Holtta E, Haaranen P, Elfving K. Polyamines and polyamine-metabolizing enzyme activities in human semen. Clin Chim Acta 1973; 48: 393-401.
65. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 1999; 5: 143-7.
66. Pegg AE, Lockwood DH, Williams AH. Concentrations of putrescine and polyamines and their enzymic synthesis during androgen-induced prostatic growth. Biochem J 1970; 117: 17-31.
67. Fjosne HE, Strand H, Sunde A. Dose-dependent induction of ornithine decarboxylase and S-adenosylmethionine decarboxylase activity by testosterone in the accessory sex organs of male rats. Prostate 1992; 21: 239-45.
68. Crozat A, Palvimo JJ, Julkunen M, Janne OA. Comparison of androgen regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organs. Endocrinology 1992; 130: 1131-44.
69. Betts AM, Waite I, Neal DE, Robson CN. Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. FEBS Lett 1997; 405: 328-32.
70. Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 1997; 158: 222-7.
71. Chang CS, Saltzman AG, Hiipakka RA, Huang IY, Liao SS. Prostatic spermine-binding protein. Cloning and nucleotide sequence of cDNA, amino acid sequence, and androgenic control of mRNA level. J Biol Chem 1987; 262: 2826-31.
72. Goueli SA, Davis AT, Hiipakka RA, Liao SS, Ahmed K. Polyamine-stimulated phosphorylation of prostatic spermine-binding protein is mediated only by cyclic AMP-independent protein kinases. Biochem J 1985; 230: 293-302.
73. Rubinstein S, Breitbart H. Cellular localization of polyamines: cytochemical and ultrastructural methods providing new clues to polyamine function in ram spermatozoa. Biol Cell 1994; 81: 177-83.
74. Hakovirta H, Keiski A, Toppari S, Halmeryto M, Abhonen L, Janne J, Parvinen M. Polyamines and regulation of spermatogenesis: selective stimulation of late spermatogonia in transgenic mice overexpressing the human ornithine decarboxylase gene. Mol Endocrinol 1993; 7: 1430-6.
75. Romijn JC. Polyamines and transglutaminase actions. Andrologia 1990; 1: 83-91.
76. Heston WD, Kadman D, Lazan DW, Fair WR. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine. Prostate 1982; 3: 383-9.
77. Saverio B, Pierpaola D, Serenella A, Casare C, Bruno M, Auro T, Arnaldo C. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000; 60: 28-34.
78. Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MRS of prostatic tissue focused on the identification of spermine: a possible biomarker of malignant behavior in prostate cancer. Magn Reson Mater Biol Phys Med 2000; 10: 153-9.
79. Moulinoux JP, Quemener V, Delcros JG, Cipolla B. Circulating polyamines as biological markers for cancer. In: Polyamines in Cancer Basic Mechanisms and Clinical Approaches Nishioka K, ed. Austin: RG Landis, 1996; 233-49.
80. Smith RC, Litwin MS, Lu Y, Zetter BR. Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nat Med 1995; 1: 1040-5.
81. Koike C, Chao DT, Zetter BR. Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res 1999; 59: 6109-12.
82. Iwata S, Sato Y, Asada M, Takagi M, Tsujimoto A, Inaba T, Yamada T, Sakamoto S, Yata J, Shimogori T, Igarashi K, Mizutani S. Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation. Oncogene 1999; 18: 165-72.
83. Romijn JC. Polyamine requirement of prostate cancer cell proliferation. In: Molecular and cellular biology of prostate cancer. Karr JP, Coffey DS, Smith RG, Tindall DJ, ed. New York: Plenum Press, 1991; 103-14.
84. Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G. Lowdose difluoromethylornithine and polyamine levels in human prostate tissue. J Natl Cancer Inst 1999; 91: 1416-7.
85. Meyskens FLJ, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999; 5: 945-51.
86. Dunzendorfer U, Releyea N, Whitmore WF, Fogh J, Balis ME. Some effects of inhibitors of polyamine biosynthesis on experimental prostatic cancer. Drug Res 1984; 34: 36-9.
87. Palyi I, Kremmer T, Kalnay A, Turi G, Mihalik R, Bencsik K, Boldizsar M. Effects of methylacetylenic putrescine, an ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines. Anticancer Drugs 1999; 10: 103-11.
88. Pinto JT, Qiao C, Xing J, Rivlin RS, Protomastro ML, Weissler M, Tao Y, Thaler H, Heston WD. Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am J Clin Nutr 1997; 66: 398-405.
89. Gupta S, Ahmad N, Mohan RR, Husan MM, Mukhtar H. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999; 59: 2115-20.
90. McCloskey DE, Woster PM, Casero RA, Davidson NE. Effects of the polyamine analogues N1-ethyl-N11-((cyclopropyl)methyl)-4,8-diazaundecane and N1-ethylN-11-((cycloheptyl)methyl)-4,8-diazaundecane in human prostate cancer cells. Clin Cancer Res 2000; 6: 17-23.
91. Zagaja GP, Shrivastav M, Fleig MJ, Marton LS, Rinker-Schaeffer CW, Dolan ME. Effects of polyamine analogues on prostatic adenoca adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 1998; 41: 505-12.
92. Eiseman JL, Roger FA, Guo Y, Kauffman S, Sentz DL, Klinger MF, Callery PS, Kyprianou N. Tumor targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer. Cancer Res 1998; 58: 4864-70.
93. Jeffers L, Church D, Basu H, Marton L, Wilding G. Effects of the polyamine analogues BE-4-4-4-4, BE-3-7-3, and BE-3-3-3 on the proliferation of three prostate cancer cell lines. Cancer Chemother Pharmacol 1997; 40: 172-9.
94. Heston WD, Yang CR, Pliner L, Russo P, Covey DF. Cytotoxic activity of a polyamine analogue, monoaziridinyl-putrescine, against the PC-3 human prostatic carcinoma cell line. Cancer Res 1987; 47: 3627-31.
95. McCloskey DE, Yang J, Woster PM, Davidson NE, Casero RA. Polyamine analogue induction of programmed cell death in human lung tumor cells. Clin Cancer Res 1996; 2: 441-6.
96. Mi Z, Kramer DL, Miller JT, Bergeron RJ, Bernacki R, Porter CW. Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogues and inhibitors. Prostate 1998; 34: 51-60.
97. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrin Rev 1999; 20: 501-34.
98. Morgan DO, Fisher RP, Espinoza FH, Farrell A, Nourse J, Chamberlin H, Jin P. Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases. Cancer J Sci Am 1998; 1: 77-83.
99. Macrae M, Plasterk RH, Coffino P. The ornithine decarboxylase gene of Caenorhabditis elegans: cloning, mapping and mutagenesis. Genetics 1995; 140: 517-25.
100. Macrae M, Kramer DL, Coffino P. Developmental effect of polyamine depletion in Caenorhabditis elegans. Biochem J 1998; 333: 309-15.
101. Nishimura K, Nakatsu F, Kashiwagi K, Ohno H, Saito T, Igarashi K. Essential role of S-adenosylmethionine decarboxylase in mouse embryonic development. Genes Cells 2002; 7: 41-7.
102. Persson K, Holm I, Heby O. Cloning and sequencing of an intronless mouse S-adenosylmethionine decarboxylase gene coding for a functional enzyme strongly expressed in the liver. J Biol Chem 1995; 270: 5642-8.
103. Bergeron RJ, Weimar WR, Müller R, Zimmerman OC, McCosar HB, Yao H, Smith RE. Effect of polyamine analogues on hypusine content in JURKATT-cells. J Med Chem 1998; 41: 3901-8.
104. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
105. Chellappan SP, Giordano A, Fisher PB. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development, in cyclin dependent kinase (CDK) inhibitors. Vogt PK, Reed SI, eds. Springer-Verlag: Berlin, 1998; 57-103.
106. Gray N, Detivaud L, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 1999; 6: 859-75.
107. Meijer L, Leclerc S, Leost M. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol Ther 1999; 82: 279-84.
108. Sielecki TM, Boylan JF, Benfield PA, Trainor GL. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 2000; 43: 1-18.
109. Amanatullah DF, Reutens B, Zafonte B, Fu M, Mani S, Pestell RG. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 2000; 5: 372-90.
110. Reutens AT, Pestell RG. Royal Australian College of Physicians. J. Fellowship Affairs, Countinuing Education Series, Sydney, 1997; 4-13.
111. Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994; 224: 771-86.
112. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527-36.
113. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Tren Cell Biol 1996; 6: 393-7.
114. Meijer L, Kim SH. Chemical inhibitors of cyclin-dependent kinases. Meth Enzymol: 1997; 283: 113-28.
115. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997; 40: 408-12.
116. Hajduch M, Havlieek L, Vesely J, Novotny R, Mihal V, Strnad M. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv Exp Med Biol 1999; 457: 341-53.
117. Krystof V, Lenobel R, Havlícek L, Kuzma M, Strnad M. Synthesis and biological activity of olomoucine II. Bio Med Chem Lett 2002; 12: 3283-6.
118. Mad'arova J, Lukesova M, Hlobilkova A, Strnad M, Vojtesek B, Lenobel R, Hajduch M, Murray PG, Perera S, Kolar Z. Synthetic inhibitors of CDKs induce different responses in aandrogen sensitive and androgen insensitive prostatic cancer cell lines. Mol Path 2002; 55: 227-34.